Navigation Links
Researchers issue outlook for a significant New England 'red tide' in 2010
Date:2/24/2010

Today, scientists from the NOAA-funded Gulf of Maine Toxicity (GOMTOX) project issued an outlook for a significant regional bloom of a toxic alga that can cause 'red tides' in the spring and summer of this year, potentially threatening the New England shellfish industry.

An abundant seed population in bottom sediments has set the stage for a significant bloom of the toxic alga Alexandrium fundyense. This organism swims in the water, and divides again and again to form a "bloom" or red tide, but it also produces dormant cells or cysts that fall to the ocean bottom at the end of these blooms.

A cyst survey conducted in late 2009 shows the highest amount of cysts the team has ever measured, more than 60 percent higher than what was observed prior to the historic red tide of 2005. The cyst bed also appears to have expanded to the south, and thus the 2010 bloom may affect areas such as Massachusetts Bay and Georges Bank sooner than has been the case in past years.

This year's bloom could be similar to the major red tides of 2005 and 2008, according to Woods Hole Oceanographic Institution (WHOI) biologist Don Anderson, principal investigator of the GOMTOX study. The 2005 bloom shut down shellfish beds from Maine to Martha's Vineyard (Mass.) for several months and caused an estimated $20 million in losses to the Massachusetts shellfish industry alone. The 2008 outbreak was similar in scale.

Although the algae in the water pose no direct threat to human beings, the toxins they produce can accumulate in filter-feeding organisms such as mussels and clams which can cause paralytic shellfish poisoning (PSP) in humans who consume them.

In order to protect public health, shellfish beds are closed when toxicities rise above a quarantine leveloften during the peak harvesting season. Due to effective monitoring by state agencies, there have been no illnesses from legally harvested shellfish in recent yearsdespite some severe b
'/>"/>

Contact: WHOI Media Relations
media@whoi.edu
508-289-3340
Woods Hole Oceanographic Institution
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... virus discovered last year in a rare form of skin ... most common form of skin cancer among Americans, according to ... James Cancer Hospital and Solove Research Institute. The researchers examined ... a highly curable form of skin cancer that is expected ...
... A team of 80 researchers from more than ... Environmental and Cultural Change in Maryland,s Coastal Bays, a ... making up Maryland,s Atlantic coastline. Published by IAN ... setting, context and ecology of these waterways, their islands ...
... adults who have less strength, poor physical function and low muscle ... with more strength and better function. That,s the finding of a ... . The study also found that muscle density, a measure ... the muscle, is a more accurate gauge of a person,s risk ...
Cached Biology News:Study links virus to some cases of common skin cancer 2Reducing risk of hospitalization in the elderly 2
(Date:6/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lkcspr/2015_strategies ... "2015 Strategies in European Immunoprotein Diagnostic ... This new 273-page report provides ... including emerging tests, technologies, instrumentation, sales forecasts, ... suppliers. Companies Mentioned: - ...
(Date:6/1/2015)... June 1, 2015  OncoSec Medical Inc. ("OncoSec") ... intratumoral cancer immunotherapies, today announced a collaboration with ... Veterinary Medicine to test ImmunoPulse™ IL-12 as an ... primary goals of the canine study are to ... of ImmunoPulse™ IL-12 and validate key clinical biomarkers. ...
(Date:6/1/2015)... Hutchison China MediTech Limited ... (publ) ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, ... clinical trial of HMP,s c-Met inhibitor savolitinib (AZD6094) ... cell lung cancer ("NSCLC"). AZD9291 is ... receptor (EGFR). Preliminary data on the activity of ...
(Date:5/31/2015)... 31, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... oncology and drug-delivery therapies, today announced interim findings ... its investigational new drug PEGPH20 for the potential ... The encouraging interim data was presented today ... meeting in an oral presentation by Principal Investigator ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... AMGN ) Senior Vice President of Research and ... U.S. Food and Drug Administration (FDA) panel charged with implementing ... patient safety and follow a science-based approach. "Put ... "Amgen believes biosimilars have a meaningful role to play in ...
... November 1, 2010 ... ... --> ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Influenza Vaccine ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Biology Technology:Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 2Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 3Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 4Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 5Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 6Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 7Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 8Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 9Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 2Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 3Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 4Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 5Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 6Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 7Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 8
Nestin, Human...
Ezrin/Radixin/Moesin Antibody...
... Taura Syndrome Virus Coat Protein ... tested applications). ... MNDIPITNQN VVLSKNVTDN LFEVQDQALI ESLSRDVLLH NDSWTSSDDE ... terminal amino acids 25/100 of ...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Biology Products: